Biocon Biologics, a subsidiary of Biocon today announced that the company has completed the integration of the acquired biosimilars business in over 70 countries in Emerging Markets effective 01 July 2023, increasing the scale and scope of its business.
Following the deal closure in November 2022, this marks the first wave of countries where Viatris' operations have fully transitioned to Biocon Biologics. A robust integration plan has ensured a seamless transition of partners, people, systems, and processes across these countries.
The existing commercialized portfolio of biosimilars, including bTrastuzumab, bPegfilgrastim, bBevacizumab, bGlargine, bAspart, bAdalimumab, and bEtanercept, managed by Viatris in these
markets, is now a part of Biocon Biologics' commercial organization.
'We will work with existing and new partners to expand our footprint and strengthen our business presence in these countries. Our best-in-class R&D capabilities, high-quality manufacturing, supply chain excellence, and commercial and regulatory expertise will enable us to expand access to a diverse portfolio of biosimilars, meet patients' needs and be a trusted partner to patients and the healthcare community in these markets.', the company commented.
|